A5041727274- Sexual function and dysfunction studies
- Urinary Bladder and Prostate Research
- Hormonal and reproductive studies
- Phosphodiesterase function and regulation
- Sexual Differentiation and Disorders
- Sexuality, Behavior, and Technology
- Migraine and Headache Studies
- Urological Disorders and Treatments
- Nitric Oxide and Endothelin Effects
- Urologic and reproductive health conditions
- Genital Health and Disease
- Neuropeptides and Animal Physiology
- Marriage and Sexual Relationships
- Neuroendocrine regulation and behavior
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Growth Hormone and Insulin-like Growth Factors
- Endometriosis Research and Treatment
- Pelvic floor disorders treatments
- Prostate Cancer Diagnosis and Treatment
- Pharmacology and Obesity Treatment
- Cannabis and Cannabinoid Research
- Urinary and Genital Oncology Studies
- Reproductive System and Pregnancy
- Ion Channels and Receptors
- Pharmacological Effects and Toxicity Studies
Medizinische Hochschule Hannover
2015-2024
Hannover Re (Germany)
2016
Weatherford College
2014
Ludwig-Maximilians-Universität München
2012
Agaplesion Markus Hospital
2009
Bayer (Germany)
2009
Institut für biologische Forschung
2008
Lund University
2007
University of Münster
2004
University of Zurich
2003
Current pharmacological concepts in the treatment of benign prostatic hyperplasia are aimed at static and dynamic component disease. Mainly alpha-blocking agents used to reduce adrenergic tone myocytes, thus, increasing urine flow through urethra by reducing urethral resistance. With introduction phosphodiesterase (PDE) 5 inhibitor sildenafil concept PDE inhibition has gained tremendous interest field urology. We characterized isoenzymes from human tissue molecular biology protein chemistry,...
Phosphodiesterases (PDE) are key enzymes in the regulation of smooth muscle tone. Experimental studies showed PDE III and V-isoenzymes to play an important role tone corpus cavernosum. Recently, a specific III-inhibitor (milrinone) V-inhibitor (sildenafil) were introduced clinical studies. An experimental study was done examine potential PDE-inhibitors treatment erectile dysfunction.In organ bath, strips from human rabbit cavernosum precontracted increasing doses inhibitors added. In...
Orally active, selective inhibitors of phosphodiesterase type 5 (PDE 5, cyclic GMP PDE), such as sildenafil, tadalafil and vardenafil, are currently the first-choice treatment options for clinical management erectile dysfunction (ED) various etiologies severities. However, a significant number patients remain dissatisfied with available therapies due lack efficacy or discomfort arising from adverse events. Several new PDE5 inhibitors, among which avanafil (TA-1790), lodenafil, mirodenafil,...
Knowledge of intracellular signal propagation in smooth muscle tone regulation is major importance the understanding physiology penile erection, and development new selective pharmacological agents for treatment related disorders. Since phosphodiesterases (PDE) are key enzymes signaling pathway, we elucidate their presence potential functional relevance human cavernous tissue.To identify PDE messenger RNA tissue, constructed primers 14 published isoforms. Expression genes was then analyzed...